AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement
SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Marco Londei, M.D. as Chief Development Officer. Dr. Londei will lead the preclinical and clinical development of AnaptysBio's proprietary antibody pipeline.
"We are pleased to welcome Dr. Londei to AnaptysBio's executive leadership team," said Hamza Suria, President and Chief Executive Officer of AnaptysBio. "Dr. Londei's extensive expertise includes successful translational and clinical development of monoclonal antibodies and small molecules for dermatology, rheumatology, neurology, oncology and allergy. Novel anti-inflammatory programs are a strategic priority for AnaptysBio's proprietary pipeline, particularly our first-in-class anti-IL-33 antibody program applicable to a variety of Th2-driven diseases."
Dr. Londei joins AnaptysBio from Bristol-Myers Squibb (BMS) where he was Therapeutic Area Head, Immunosciences and responsible for early clinical and translational research for a portfolio of immune-related therapeutics. Prior to BMS, Dr. Londei was Global Head of Autoimmunity Translational Medicine at Novartis, and Translational Science Officer for the Genomics Institute of the Novartis Research Foundation. He led the design and execution of more than 70 early stage clinical studies at Novartis and BMS, including the development of secukinumab, canakinumab and several other biologic therapies for immune-mediated inflammatory diseases.
Dr. Londei received his M.D. from the Faculty of Medicine at University of Bologna and has conducted post-doctoral studies at Tumor Immunology Unit, London, UK. He was a key member of the team which pioneered the development of anti-TNF therapies while at the Kennedy Institute of Rheumatology (KIR) Faculty of Medicine Imperial College, London with Professors Ravinder Maini and Marc Feldmann. Dr. Londei was Professor at the Faculty of Medicine Imperial College London, and then Professor of Autoimmunity and Gastroenterology Consultant at University College London prior to joining Novartis. He is a widely recognized world-class contributor in inflammation, and has published over 160 peer-reviewed papers in the fields of autoimmunity, self-recognition and immune modulatory checkpoints.
About AnaptysBio
AnaptysBio is a privately-held company focused on the generation of antibody therapeutics and is the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. AnaptysBio is developing a pipeline of therapeutic antibody candidates, including novel programs in immuno-oncology, inflammation, fibrosis and muscle wasting disorders. AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation in mammalian cells, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with Merck, Roche, Novartis, Celgene, Gilead, Momenta, DARPA, DTRA and TESARO. For more information, visit www.anaptysbio.com.
Logo - http://photos.prnewswire.com/prnh/20111205/SF16052LOGO
Contacts:
Julie Rathbun
[email protected]
206-769-9219
SOURCE AnaptysBio
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article